[go: up one dir, main page]

WO2000045800A3 - Immunosurpressive effects of pteridine derivatives - Google Patents

Immunosurpressive effects of pteridine derivatives Download PDF

Info

Publication number
WO2000045800A3
WO2000045800A3 PCT/EP2000/000938 EP0000938W WO0045800A3 WO 2000045800 A3 WO2000045800 A3 WO 2000045800A3 EP 0000938 W EP0000938 W EP 0000938W WO 0045800 A3 WO0045800 A3 WO 0045800A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunosurpressive
effects
pteridine derivatives
treatment
pteridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/000938
Other languages
French (fr)
Other versions
WO2000045800A2 (en
Inventor
Mark Jozef Albert Waer
Piet Andre Maurits M Herdewijn
Wolfgang Eugen Pfleiderer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Original Assignee
Katholieke Universiteit Leuven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven filed Critical Katholieke Universiteit Leuven
Priority to CA002361561A priority Critical patent/CA2361561A1/en
Priority to EP00902660A priority patent/EP1187615A2/en
Priority to JP2000596920A priority patent/JP2002536320A/en
Priority to AU24418/00A priority patent/AU780284B2/en
Publication of WO2000045800A2 publication Critical patent/WO2000045800A2/en
Anticipated expiration legal-status Critical
Publication of WO2000045800A3 publication Critical patent/WO2000045800A3/en
Priority to US10/444,158 priority patent/US6946465B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to a pharmaceutical composition for the treatment of autoimmuno disorders and/or for the treatment or prevention of transplant-rejections comprising a pteridine derivative of general formula (I) especially a lumazine optionally combined with a second active agent.
PCT/EP2000/000938 1999-02-02 2000-02-02 Immunosurpressive effects of pteridine derivatives Ceased WO2000045800A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002361561A CA2361561A1 (en) 1999-02-02 2000-02-02 Immunosurpressive effects of pteridine derivatives
EP00902660A EP1187615A2 (en) 1999-02-02 2000-02-02 Immunosurpressive effects of pteridine derivatives
JP2000596920A JP2002536320A (en) 1999-02-02 2000-02-02 Immunosuppressive effects of pteridine derivatives
AU24418/00A AU780284B2 (en) 1999-02-02 2000-02-02 Immunosurpressive effects of pteridine derivatives
US10/444,158 US6946465B2 (en) 1999-02-02 2003-05-23 Immunosuppressive effects of pteridine derivatives

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11829599P 1999-02-02 1999-02-02
US11828299P 1999-02-02 1999-02-02
US11823599P 1999-02-02 1999-02-02
US60/118,282 1999-02-02
US60/118,295 1999-02-02
US60/118,235 1999-02-02

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09890500 A-371-Of-International 2001-10-30
US10/444,158 Continuation-In-Part US6946465B2 (en) 1999-02-02 2003-05-23 Immunosuppressive effects of pteridine derivatives

Publications (2)

Publication Number Publication Date
WO2000045800A2 WO2000045800A2 (en) 2000-08-10
WO2000045800A3 true WO2000045800A3 (en) 2002-01-10

Family

ID=27382128

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/000938 Ceased WO2000045800A2 (en) 1999-02-02 2000-02-02 Immunosurpressive effects of pteridine derivatives

Country Status (5)

Country Link
EP (1) EP1187615A2 (en)
JP (1) JP2002536320A (en)
AU (1) AU780284B2 (en)
CA (1) CA2361561A1 (en)
WO (1) WO2000045800A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276506B2 (en) 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
US6946465B2 (en) * 1999-02-02 2005-09-20 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
SE9903544D0 (en) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
HUP0301573A3 (en) 2000-02-16 2004-03-29 Neurogen Corp Branford Substituted arylpyrazines, pharmaceutical compositions containing them and their use
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
SE0003828D0 (en) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
SE0101322D0 (en) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
US7179807B2 (en) 2002-08-20 2007-02-20 Neurogen Corporation 5-substituted-2-arylpyrazines
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
US7592340B2 (en) 2003-12-04 2009-09-22 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
US10144736B2 (en) 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
SI2297106T1 (en) 2008-05-27 2014-09-30 Astrazeneca Ab Phenoxypyridinylamide derivatives and their use in the treatment of pde4 mediated disease states
US10328078B2 (en) * 2015-01-22 2019-06-25 The Scripps Research Institute Pteridine dione monocarboxylate transporter inhibitors
MY199989A (en) 2015-03-04 2023-12-02 Gilead Sciences Inc Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
ES2826748T3 (en) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivatives of 4,6-diamino-pyrido [3,2-d] pyrimidine as modulators of Toll-like receptors
AU2017318601B2 (en) 2016-09-02 2020-09-03 Gilead Sciences, Inc. Toll like receptor modulator compounds
TWI751516B (en) 2019-04-17 2022-01-01 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
TWI751517B (en) 2019-04-17 2022-01-01 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
TWI879779B (en) 2019-06-28 2025-04-11 美商基利科學股份有限公司 Processes for preparing toll-like receptor modulator compounds
NZ794369A (en) * 2020-07-03 2025-08-29 Comvita Ltd Anti-inflammatory compositions, methods and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011001A1 (en) * 1992-11-16 1994-05-26 Cell Therapeutics, Inc. Hydroxyl-containing compounds
WO1994022449A1 (en) * 1993-04-05 1994-10-13 Cell Therapeutics, Inc. Therapeutic compounds
WO1995013075A1 (en) * 1993-11-12 1995-05-18 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
WO1995031469A1 (en) * 1994-05-18 1995-11-23 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent dna probes
WO1996010568A1 (en) * 1994-09-30 1996-04-11 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists
WO1996020710A1 (en) * 1994-12-29 1996-07-11 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5641783A (en) * 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
WO1998052948A1 (en) * 1997-05-19 1998-11-26 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204612B (en) * 1987-05-14 1989-03-10 Bioresearch Spa PTERIDINS SUITABLE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR ANTI-MAGNESIC ACTIVITIES
AU4535893A (en) * 1992-06-15 1994-01-04 Regents Of The University Of California, The Screening assay for the identification of immunosuppressive drugs
WO1994014065A1 (en) * 1992-12-14 1994-06-23 Dana-Farber Cancer Institute, Inc. Methods for identifying and using immunosuppressant compounds
IL109161A0 (en) * 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5663335A (en) * 1996-03-01 1997-09-02 Pharmagenesis, Inc. Immunosuppressive compounds and methods
WO1997039358A1 (en) * 1996-04-15 1997-10-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services In vitro prognostic test for progressors and non-progressors after hiv infection

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011001A1 (en) * 1992-11-16 1994-05-26 Cell Therapeutics, Inc. Hydroxyl-containing compounds
WO1994022449A1 (en) * 1993-04-05 1994-10-13 Cell Therapeutics, Inc. Therapeutic compounds
WO1995013075A1 (en) * 1993-11-12 1995-05-18 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
US5641783A (en) * 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
WO1995031469A1 (en) * 1994-05-18 1995-11-23 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent dna probes
WO1996010568A1 (en) * 1994-09-30 1996-04-11 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists
WO1996020710A1 (en) * 1994-12-29 1996-07-11 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
WO1998052948A1 (en) * 1997-05-19 1998-11-26 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BUU-HOI, N. P. ET AL: "Phthalonimides (1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolines) of potential biological interest", J. HETEROCYCL. CHEM., vol. 5, no. 4, 1968, pages 545 - 547, XP000906859 *
COTTAM ET AL: "Substituted Xanthines, Pteridinediones, and Related Compounds as Potential Antiinflammatory Agents. Synthesis and Biological Evaluation of Inhibitors of Tumor Necrosis Factor-alpha", J. MED. CHEM., vol. 39, no. 1, 1996, pages 2 - 9, XP000906858 *

Also Published As

Publication number Publication date
AU780284B2 (en) 2005-03-10
CA2361561A1 (en) 2000-08-10
JP2002536320A (en) 2002-10-29
EP1187615A2 (en) 2002-03-20
WO2000045800A2 (en) 2000-08-10
AU2441800A (en) 2000-08-25

Similar Documents

Publication Publication Date Title
WO2000045800A3 (en) Immunosurpressive effects of pteridine derivatives
CA2356380A1 (en) Immunosuppressive effects of pteridine derivatives
IL162214A (en) Pyridine derivatives and pharmaceutical compositions containing the same
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
WO2004078712A3 (en) Isoquinoline derivatives and methods of use thereof
BG106030A (en) Pharmaceutical composition
CA2392879A1 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
WO2003053359A3 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
AU3076700A (en) 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient
WO2003013541A8 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
WO2001062737A3 (en) Amino pyrazole derivatives useful for the treatment of obesity and other disorders
ZA200110504B (en) Dietary or pharmaceutical compositions for use for the prevention or treatment of hyperoxaluria.
WO2004005286A3 (en) Viral inhibitors
CA2294913A1 (en) Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative
WO2001035950A3 (en) Benzamide therapeutics and methods for treating inflammatory bowel disease
YU87202A (en) Arylmethylamine derivatives for use as tryptase inhibitors
AU2001284413A1 (en) Medicinal compositions for preventing or treating heart failure
MXPA03010761A (en) Pharmaceutical combinations.
PL346764A1 (en) New oral formulation for 5-ht4
DE69931378D1 (en) CHINAZOLINE DERIVATIVES AND THERAPEUTIC USES THEREOF
EP0842663A4 (en) Ophthalmic preparations
HUP0202725A3 (en) Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity, process for their preparation and pharmaceutical compositions containing them
WO2002080978A3 (en) Pharmaceutical compositions comprising ascomycin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2361561

Country of ref document: CA

Ref country code: CA

Ref document number: 2361561

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 24418/00

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 596920

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000902660

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09890500

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000902660

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 24418/00

Country of ref document: AU